Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder

NCT03420222 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
10
Enrollment
INDUSTRY
Sponsor class

Stopped Due to limited enrollment (N=10), this clinical trial was terminated by the Sponsor.

Conditions

Interventions

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.